Open AccessRevendo o tratamento para pneumonia causada por Staphylococcus aureus resistente à meticilina
Author(s) -
Márcia Farsura de Oliveira,
Caroline Silva de Araújo Lima,
Rômulo Daniel Sanches,
Jemerson Costa da Silva,
Thaísa Munique Ferreira Costa de Oliveira,
Isa Vitória Gonçalves Araújo,
Rubenrhaon Alberto Paulino,
Mona Khaled Abdul Rahim,
Gabryelle Moreira Corrêa,
Ana Gabrielly Masson Itacarambi,
Gustavo Henrique Silva Ribeiro,
Anderson Poubel Batista,
Melo Grillo
Publication year - 2022
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v11i1.24338
Subject(s) - linezolid , medicine , pneumonia , vancomycin , intensive care medicine , staphylococcus aureus , adverse effect , empyema , sepsis , surgery , biology , bacteria , genetics
Methicillin-resistant Staphylococcus aureus (MRSA) can cause several infections, both dermatological and invasive infections, such as pneumonia, empyema and sepsis. Due to its importance and pathogenicity, it is considered a worldwide public health problem, which implies the need to search for more efficient therapeutic regimens. Specifically for the treatment of MRSA pneumonia, vancomycin and linezolid are the main drugs used. Objective: The main objective of this study was to compare the two drugs in terms of their effectiveness in the treatment of MRSA pneumonia, through a review of the most recent aspects of the literature. Methodology: Through a narrative review, the pros and cons of each therapeutic intervention were investigated, as well as the individual pharmacological aspects and the pathophysiology of the bacterial infection in question. Conclusion: Finally, it was concluded that linezolid is superior to vancomycin, with better rates of reduced mortality and length of hospital stay, along with a lower risk of complications and adverse events, in addition to greater therapeutic flexibility, better cost-effectiveness and lower resistance rates.